🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

Akumentis Healthcare income crosses Rs 400 Cr in FY24; posts Rs 57 Cr profit

EntrackrEntrackr · 1y ago
Akumentis Healthcare income crosses Rs 400 Cr in FY24; posts Rs 57 Cr profit
Medial

Pharmaceutical company Akumentis Healthcare has reported a flat scale during the last fiscal year ending March 2024. However, the controlled cost mechanism helped the Thane-based firm to improve its margins and bottom line during the same period. Akumentis Healthcare saw a modest 2.8% increase in its scale to Rs 398 crore in FY24 from Rs 387 crore in FY23, its standalone financial statements filed with the Registrar of Companies show. *Note: Akumentis Healthcare is a wholly-owned subsidiary of Akum Drugs and Pharma Ltd which recorded a 14.3% increase in revenue to Rs 4,178 crore in FY24 from Rs 3,655 crore in FY23. Founded in 2010, Akumentis Healthcare provides medicinal products including creams and medicines across dermatology, orthopedics, gynecology, critical care, cardiovascular, diabetes, and pediatrics. The sale of these products was the sole source of revenue for the company. Akumentis made Rs 10 crore from interest and other miscellaneous sources tallying its overall income to Rs 409 crore in FY24. When it comes to burn, around 36.6% (Rs 122 crore) of its total burn went to employee benefits while cost of material consumed 31.5% (Rs 105 crore) of the overall expenditure in FY24. Its marketing (advertising cum promotion), commission paid to selling agents, traveling, legal and other overheads took Akumentis’ total expenditure to Rs 333 crore in FY24 from Rs 340 crore in FY23. Check TheKredible for more details. The controlled spending on employee benefits and related expenses helped Akumentis Healthcare increase its margins. As a result, the firm’s profit spiked 62.9% to Rs 57 crore in FY24 from Rs 35 crore in FY23. Its ROCE and EBITDA margin improved to 57.46% and 62.90%, respectively. On a unit level, Akumentis spent Rs 0.84 to earn a rupee. FY23-FY24 FY23 FY24 EBITDA Margin 19.26% 62.90% Expense/₹ of Op Revenue ₹0.88 ₹0.84 ROCE 65.38 57.46 Rajaram Samant, who was the co-founder and chief executive officer of Akumentis Healthcare for nearly 10 years, left the company in February 2020. Samant had previously worked at three large public companies: Ranbaxy, Emcure and Wanbury. In 2015, Peak XV had led a $19 million round in Akumentis.

Unicommerce profits grew 22% in Q1 FY25

EntrackrEntrackr · 10m ago
Unicommerce profits grew 22% in Q1 FY25
Medial

Unicommerce, the e-commerce SaaS platform, has announced its results for the first quarter of the ongoing fiscal year. The Gurugram-based company saw a 3% increase in revenue and 22% increase in profit in the first quarter of the ongoing fiscal year as compared to Q1 FY24. Unicommerce’s revenue from operations increased to Rs 27.4 crore in Q1 FY25, from Rs 26.5 crore in Q4 FY24, its audited financial statements sourced from National Stock Exchange (NSE) shows. For background, its operating revenue increased by 15% to Rs 103 crore in the last fiscal year (FY24) from Rs 90 crore in FY23. Unicommerce offers integrated e-commerce enablement SaaS solutions including inventory, return, and omnichannel management. Besides India, Unicommerce operates in Indonesia, Philippines, Singapore, Malaysia, UAE & Saudi Arabia among others. Unicommerce spending on employee benefits, server hosting, finance, legal, and other overheads took the firm’s overall cost to Rs 24.2 crore in Q1 FY25 from Rs 23.9 crore in Q4 FY24. The modest increase in controlled expenditure helped Unicommerce to grow its profits by 22% to Rs 3.5 crore in Q1 FY25 from Rs 2.87 crore in Q4 FY24. On a unit level, it spent Rs 0.88 to earn a rupee in Q1 FY25. The Gurugram-based firm had launched an IPO of Rs 276 crore, open to the public from August 2 to August 6, with a price band of Rs 102-108 per share. Unicommerce’s popularity was evident in its oversubscription rate, which soared over 168 times. The firm is currently trading at Rs 221.97 (as of the end of August 30) with a market capitalization of Rs 2,273 crore (approximately $274 million).

Download the medial app to read full posts, comements and news.